Diabetic Gastroparesis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Diabetic Gastroparesis Market Outlook

Thelansis’s “Diabetic Gastroparesis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Gastroparesis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Gastroparesis Overview

Gastroparesis is characterized by a measurable delay in gastric emptying, devoid of any indications of mechanical blockage. In cases of poorly managed diabetes, diabetic gastroparesis can arise, stemming from disruptions in the autonomic nervous system, neurons, specialized pacemaker cells (interstitial cells of Cajal, ICC) in the stomach and intestine, and the smooth muscle cells in the gastrointestinal tract. Poorly controlled diabetes often leads to hyperglycemia (blood glucose exceeding 200 mg/dL), a contributing factor to diabetic gastroparesis due to neuropathy resulting from prolonged hyperglycemia. Unlike acute hyperglycemia, which can cause delayed gastric emptying but is usually reversible with improved glycemic control, chronic hyperglycemia-associated gastroparesis does not resolve as readily. Gastric emptying hinges on the synchronization of fundal tone and antral phasic contraction, coupled with the simultaneous inhibition of pyloric and duodenal contractions. This coordination relies on interactions between the enteric and autonomic nervous systems, smooth muscle cells, and the specialized pacemaker cells in the stomach (myenteric interstitial cells of Cajal). Initial management of symptomatic gastroparesis frequently involves lifestyle adjustments. Achieving optimal glycemic control in diabetic patients can mitigate the impact of hyperglycemia-induced delayed gastric emptying. Common recommendations include:

• Consuming smaller, more frequent meals.
• Minimizing carbonated beverages.
• Increasing liquid intake.
• Reducing fat and fiber content.

Discouraging alcohol and smoking is essential, as they can exacerbate symptoms. The prognosis of diabetic gastroparesis lacks a clear definition and hinges on controlling hyperglycemia and adhering to medications. The condition adversely affects quality of life and can lead to significant morbidity if left unchecked. Educating individuals about the lifelong management of this condition is crucial for improving clinical outcomes. Gastroparesis, a manifestation of autonomic neuropathy, is most prevalent in individuals with diabetes for over a decade and who have already developed other microvascular complications. Once gastroparesis symptoms manifest, they typically endure and remain stable for 12–25 years, even with controlled blood glucose levels. Common symptoms include early satiety, nausea, bloating, abdominal pain, and vomiting. Primary treatments for diabetic gastroparesis involve dietary adjustments, glycemic control, and fluid and electrolyte restoration. For mild cases, dietary modifications are often the initial approach. Estimates suggest that 4% in the U.S. population, 30% in type 2 diabetes (T2DM), and up to 58% in type 1 diabetes (T1DM).

• The age-adjusted incidence rate of gastroparesis is 2.4/100,000 person-years in men and 9.8/100,000 person-years in women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: